Back to Results

Merck KGaA ADR (MKKGY)

Merck KGaA ADR is a depositary receipt representing common stock of Merck KGaA, a science and technology company headquartered in Darmstadt, Germany, and listed on OTC Markets. Through its operating businesses, Merck KGaA serves customers across Europe, North America, Latin America, the Middle East and Africa, and the Asia Pacific region. Its Life Science segment supplies products, tools, and services for research, testing, and bioprocessing applications, while the Healthcare segment develops, manufactures, and markets prescription medicines and biopharmaceuticals in areas including oncology, rare diseases, neurology, immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment focuses on materials and solutions used in semiconductor and display-related applications. Founded in 1668, Merck KGaA is a subsidiary of E. Merck KG.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-MKKG.Y
$34.63
13.7% Upside
Fair
$36.02
18.3% Upside
Undervalued
Good
1.1%
November 12, 2026
24.4x
1.9x
2.7x
66.282 B
75.548 B
17.5%
29.7%
10.0
43.8%
114.9%
Valuation • Fair Value

Merck KGaA ADR (OTC-MKKG.Y) Fair Value by Valuation Model

Review the available estimates for Merck KGaA ADR (OTC-MKKG.Y), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$34.63

Estimated upside of 13.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$37.05

Discounted cash flow valuation reference.

Ben Graham Formula Value

$14.02

Classic Ben Graham valuation formula reference.

DDM Fair Value

$39.66

Dividend discount model valuation reference.

EPV Fair Value

$23.22

Earnings power value estimate.

Comps Fair Value

$32.43

Comparable-company valuation reference.

Analyst Price Target

$36.02

Analysts imply upside of 18.3%.

How to read these valuation models

Use the 8 available valuation references for Merck KGaA ADR (OTC-MKKG.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Merck KGaA ADR (OTC-MKKG.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

24.135 B

Current operating scale indicator.

Revenue Forecast

24.622 B

Forward revenue estimate.

EBITDA

6.38 B

Current operating profitability reference.

EBITDA Forecast

7.062 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Merck KGaA ADR (OTC-MKKG.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Merck KGaA ADR (OTC-MKKG.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.61

No elevated caution signal from this screen.

Altman Z-Score

10.0

Relatively strong balance-sheet zone.

FCF / Net Income

114.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Merck KGaA ADR (OTC-MKKG.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Merck KGaA ADR (OTC-MKKG.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

1.1%

Current income yield reference.

Payout Ratio

43.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Merck KGaA ADR (OTC-MKKG.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Merck KGaA ADR (OTC-MKKG.Y) Stock Forecast & Technical Outlook

Review Merck KGaA ADR (OTC-MKKG.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Merck KGaA ADR (OTC-MKKG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Merck KGaA ADR (OTC-MKKG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Merck KGaA ADR (OTC-MKKG.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Merck KGaA ADR (OTC-MKKG.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Merck KGaA ADR (OTC-MKKG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Merck KGaA ADR (OTC-MKKG.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Merck KGaA ADR (OTC-MKKG.Y) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Merck KGaA ADR (OTC-MKKG.Y) Stock FAQ

Data-supported answers about Merck KGaA ADR (OTC-MKKG.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$34.63
Estimated upside 13.7%
Valuation Rating
Undervalued
Estimated upside of 13.7%
Analyst Target
$36.02
Implied upside 18.3%
Financial Health
Good
Current financial-health read

The current fair value estimate for Merck KGaA ADR (OTC-MKKG.Y) is $34.63. This implies an estimated upside of 13.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 13.7% versus the current market price.

The available analyst price target for Merck KGaA ADR (OTC-MKKG.Y) is $36.02. The analyst target implies estimated upside of 18.3%.

The current financial health read for Merck KGaA ADR (OTC-MKKG.Y) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Merck KGaA ADR (OTC-MKKG.Y) is November 12, 2026.

Based on the current data, dividend yield is 1.1%.

The current P/E ratio listed for Merck KGaA ADR (OTC-MKKG.Y) is 24.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Merck KGaA ADR is 66.282 B.

The current enterprise value listed for Merck KGaA ADR is 75.548 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Merck KGaA ADR is OTC-MKKG.Y, and the stock is listed on OTC Markets.

Merck KGaA ADR (OTC-MKKG.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Merck KGaA ADR is 17.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Merck KGaA ADR is 29.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B